Minirin (Desmopressin Acetate Trihydrate)

Desmopressin is a synthetic analogue of vasopressin that selectively activates V2 receptors in the kidney’s collecting ducts. This activation raises cyclic AMP, prompting aquaporin‑2 channels to move to the cell surface, which increases water reabsorption and concentrates urine. It also stimulates release of von Willebrand factor and factor VIII from endothelial cells, aiding haemostasis.

The appropriate dose of Minirin is determined by a qualified prescriber based on the patient’s specific condition, age, weight, renal function, and response to therapy. Dosage forms include injectable solutions administered intramuscularly, intravenously, or subcutaneously, and the prescribing clinician will set the exact regimen.

Safety data for Minirin in pregnancy and lactation are limited, and the product is classified as a category where benefits must be weighed against potential risks. Healthcare providers should evaluate the necessity of treatment and discuss possible effects with the patient before prescribing during pregnancy or while breastfeeding.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

Minirin (desmopressin) is a selective V2‑receptor agonist, offering a longer duration of action and fewer vasoconstrictive effects compared with natural vasopressin (ADH). Unlike non‑selective analogues, desmopressin has minimal impact on blood pressure, making it preferable for patients where cardiovascular stability is a concern.

Minirin should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

Minirin is supplied as an injectable solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and prescriber’s preference. Administration technique follows standard aseptic injection practices, and dosing intervals are individualized by the treating physician.

The most serious risks include severe hyponatremia leading to seizures or coma, water intoxication with cerebral edema, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of low sodium, rapid weight gain, or neurological changes, and treatment should be stopped if serious adverse events occur.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hypertension, and in individuals with severe renal impairment where fluid balance cannot be safely managed. It should also be avoided in patients with chronic hyponatremia or conditions predisposing to water retention.